



This is a repository copy of *First Indian report on genome-wide comparison of multidrug-resistant Escherichia coli from blood stream infections.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/158004/>

Version: Published Version

Article:

Devanga Ragupathi, N.K. orcid.org/0000-0001-8667-7132, Veeraraghavan, B., Muthuirulandi Sethuvel, D.P. et al. (7 more authors) (2020) First Indian report on genome-wide comparison of multidrug-resistant Escherichia coli from blood stream infections. PLoS ONE, 15 (2). e0220428. ISSN 1932-6203

<https://doi.org/10.1371/journal.pone.0220428>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

RESEARCH ARTICLE

First Indian report on genome-wide comparison of multidrug-resistant *Escherichia coli* from blood stream infections

Naveen Kumar Devanga Ragupathi^{1,2}, Balaji Veeraraghavan^{1*}, Dhiviya Praba Muthurulandi Sethuvel¹, Shalini Anandan¹, Karthick Vasudevan¹, Ayyan Raj Neeravi¹, Jones Lionel Kumar Daniel¹, Sowmya Sathyendra³, Ramya Iyadurai³, Ankur Mutreja^{4,5}

1 Department of Clinical Microbiology, Christian Medical College, Vellore, India, **2** Department of Chemical and Biological Engineering, The University of Sheffield, Sheffield, United Kingdom, **3** Department of Medicine, Christian Medical College, Vellore, India, **4** Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, United Kingdom, **5** Translational Health Science and Technology Institute (THSTI), Delhi-NCR, India

* vbajali@cmcvellore.ac.in



OPEN ACCESS

Citation: Devanga Ragupathi NK, Veeraraghavan B, Muthurulandi Sethuvel DP, Anandan S, Vasudevan K, Neeravi AR, et al. (2020) First Indian report on genome-wide comparison of multidrug-resistant *Escherichia coli* from blood stream infections. PLoS ONE 15(2): e0220428. <https://doi.org/10.1371/journal.pone.0220428>

Editor: Grzegorz Woźniakowski, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy w Pulawach, POLAND

Received: July 20, 2019

Accepted: February 7, 2020

Published: February 26, 2020

Copyright: © 2020 Devanga Ragupathi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The author(s) received no specific funding for this research work. DRNK is funded by the Global Challenges Research Fellowship, The University of Sheffield, UK. AM is funded by the Department of Biotechnology in India and by the National Institute for Health Research [Cambridge

Abstract

Background

Multidrug-resistant (MDR) *E. coli* with extended-spectrum β -lactamases (ESBLs) is becoming endemic in health care settings around the world. Baseline data on virulence and antimicrobial resistance (AMR) of specific lineages of *E. coli* circulating in developing countries like India is currently lacking.

Methods

Whole-genome sequencing was performed for 60 MDR *E. coli* isolates. The analysis was performed at single nucleotide polymorphism (SNP) level resolution to identify the presence of their virulence and AMR genes.

Results

Genome comparison revealed the presence of ST-131 global MDR and ST410 as emerging-MDR clades of *E. coli* in India. AMR gene profile for cephalosporin and carbapenem resistance differed between the clades. Genotypes *bla*_{CTX-M-15} and *bla*_{NDM-5} were common among cephalosporinases and carbapenemases, respectively. For aminoglycoside resistance, *rmtB* was positive for 31.7% of the isolates, of which 95% were co-harboring carbapenemases. In addition, the FimH types and virulence gene profile positively correlated with the SNP based phylogeny, and also revealed the evolution of MDR clones among the study population with temporal accumulation of SNPs. The predominant clone was ST167 (*bla*_{NDM} lineage) followed by ST405 (global clone ST131 equivalent) and ST410 (fast spreading high risk clone).

Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] in the UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

This is the first report on the whole genome analysis of MDR *E. coli* lineages circulating in India. Data from this study will provide public health agencies with baseline information on AMR and virulent genes in pathogenic *E. coli* in the region.

Introduction

Escherichia coli is the leading cause of bloodstream infections (BSIs) [1] and other common infections including urinary tract infections (UTIs). As an important commensal component of the biosphere, *E. coli* colonizes the lower gut of animals and humans and gets released in the environment.

Virulence of *E. coli* is driven by multiple factors including adhesins, toxins, siderophores, lipopolysaccharide (LPS), capsule, and invasins [2]. It has recently been reported that a large proportion of multi-drug resistant (MDR) *E. coli* carried by people is food acquired, especially from farm animals [3]. Although most of the MDR *E. coli* are reported to be community acquired, recently MDR *E. coli*, which produce extended-spectrum β -lactamases (ESBLs) have been found to be endemic in health care settings [4,5].

Among MDR *E. coli*, AMR caused by ESBL is mainly due to the *bla*_{CTX-M} family, particularly *bla*_{CTX-M-15} and *bla*₋₁₄, compared to the less frequently observed *bla*_{SHV} and *bla*_{OXA} families [6–8]. As per the literature, carbapenem resistance in *E. coli* is mostly mediated by *bla*_{OXA-48} [9], *bla*_{NDM} and *bla*_{VIM} genes [10]. Also, increasingly, resistance is being reported for fluoroquinolones and third- and fourth-generation cephalosporins and ST-131 predominates globally among such MDR *E. coli* strains [11].

This current study was aimed at identifying the predominant virulent and AMR genes in MDR *E. coli* circulating in India. Core genome phylogeny was constructed using high quality SNP profiles to analyse the genome wide factors associated with these genes in *E. coli* isolates analyzed or sequenced.

Materials and methods

Isolates and identification

A total of 99257 specimens were received at the Department of Clinical Microbiology, Christian Medical College, Vellore, India for routine screening from BSI during the year 2006 to 2016. Isolation and identification of the organism were carried out using a standard protocol as reported earlier [12]. Of the 1100 samples found culture positive for *E. coli*, 10% were resistant to carbapenems, of which 60 MDR isolates were selected for further characterization.

Antimicrobial susceptibility testing (AST)

Disc diffusion. AST testing was carried out using the Kirby-Bauer disk diffusion method. The antimicrobial agents tested were Amikacin (30 μ g), netilmicin (30 μ g), gentamycin (10 μ g), chloramphenicol (30 μ g), ciprofloxacin (5 μ g), cefotaxime (30 μ g), ceftazidime (30 μ g), ceftazidime (30 μ g), cefepime (30 μ g), piperacillin-tazobactam (100/10 μ g), ceftazidime-sulbactam (75/30), imipenem (10 μ g) and meropenem (10 μ g), tigecycline (15 μ g) and tetracycline (30 μ g) according to guidelines suggested by Clinical and Laboratory Standards Institute (CLSI) M100-S27, 2017. Quality control strains (*K. pneumoniae* ATCC 700603, *P. aeruginosa* ATCC 27853 and *E. coli* ATCC 25922) were used in all batches, as per the CLSI recommendation.

Minimum Inhibitory Concentration (MIC) for colistin. Colistin MICs for the studied isolates were determined by broth microdilution and interpreted using CLSI 2017 breakpoint recommendations. *mcr-1* positive *E. coli* with the expected range 4–8 µg/ml, *E. coli* ATCC 25922 (0.25–2 µg/ml) and *P. aeruginosa* ATCC 27853 (0.5–4 µg/ml) were used as quality and technical control (QC and TC) strains for colistin MIC determination.

Next generation sequencing and genome assembly

Genomic DNA was extracted using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). Whole genome sequencing (WGS) was performed using an Ion Torrent™ Personal Genome Machine™ (PGM) sequencer (Life Technologies, Carlsbad, CA) with 400-bp read chemistry according to the manufacturer's instructions. Data were assembled with reference *E. coli* strain (NC000913) using Assembler SPAdes v.5.0.0.0 embedded in Torrent Suite Server v.5.0.3.

Genome annotation

The assembled sequence was annotated using PATRIC, the bacterial bioinformatics database and analysis resource (<http://www.patricbrc.org>), and NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP, <http://www.ncbi.nlm.nih.gov/genomes/static/Pipeline.html>). Downstream analysis was performed using the CGE server (<http://www.cbs.dtu.dk/services>) and PATRIC. The resistance gene profile was analysed using ResFinder 2.1 from the CGE server (<https://cge.cbs.dtu.dk//services/ResFinder/>). The sequences were also screened for antimicrobial resistance genes in the Antibiotic Resistance Genes Database (ARDB) and Comprehensive Antibiotic Resistance Database (CARD) through PATRIC. Virulence genes from the genomes were identified using VirulenceFinder 2.0 (<https://cge.cbs.dtu.dk/services/VirulenceFinder/>). Serotype of the isolates were identified using SerotypeFinder 1.1 (<https://cge.cbs.dtu.dk/services/SerotypeFinder/>).

Genome based MLST analysis

Sequence types (STs) were analysed using multi-locus sequence typing (MLST) 1.8 tool (<https://cge.cbs.dtu.dk//services/MLST/>). To visualize the possible evolutionary relationships between isolates, STs of the study isolates and the globally reported strains were computed using PHYLOViZ software v2.0 based on goeBURST algorithm. The study used Warwick database for all sequence based MLST analysis of *E. coli*.

Genome comparison analyses

Gview, interactive genome viewer was used to compare the annotated *E. coli* genome arrangements with the reference *E. coli* K12 genome (NC_000913) [13]. Core genome analysis was performed using Roary: the Pan Genome Pipeline v3.11.2 from Sanger Institute [14]. The phylogenetic tree was constructed using the core SNPs using FastTree v2.1.10. To evaluate the effect of recombination regions on the *E. coli* genomes, SNIPPY was performed to retrieve core SNPs, that was followed by Genealogies Unbiased By recombinations In Nucleotide Sequences (Gubbins) algorithm [15]. The tree was constructed with midpoint rooting. Further, the tree file was visualised and analysed in iTOL v4 (<https://itol.embl.de/>). A dendrogram representing core vs pan genes was constructed using hierarchical cluster analysis with hclust method in R.

This Whole Genome Shotgun project has been deposited at GenBank under the accession numbers as mentioned in [S1 Table](#). The version described in this manuscript is version 1.

Ethical clearance

The study was approved by the Institutional Review Board and Ethical committee, Christian Medical College, Vellore, India (IRB No.: 9540 dt 22-07-2015). All the samples were fully anonymized before processing and since our study only utilised isolates received from routine blood cultures, we did not require informed written consent from the patients.

Results

Antimicrobial susceptibility

All 60 *E. coli* isolates were resistant to carbapenems, quinolones, cephalosporins and beta-lactamase inhibitors (S1 Table). Whereas all the isolates were susceptible to colistin except B7532 and B9021, which exhibited an MIC of 32 µg/ml.

Whole genome sequence analysis

Phylogeny of MDR *E. coli*. MLSTFinder revealed the different sequence types of the isolates. The study isolates belonged to 6 clonal complexes with 14 different sequence types. Few of the sequence types were observed to share same founder types revealing the evolution of these strains. CC10 and CC 405 were the two major CCs observed with ST-167, ST-410 and ST-405 as the common STs. Interestingly, nine isolates belonging to CC/ST-131 were identified, of which, all were of H-30 clade, except the isolate BA9313 (H-24).

***E. coli* genome comparison.** Whole genome composition of 60 MDR *E. coli* was compared with the *E. coli* K-12 reference genome which shows the region of differences between these genomes (S1 Fig). A total of 2,518,792 SNPs were identified in all the analyzed genomes. On minimum, 5957 and maximum, 74713 SNPs were identified in the study MDR *E. coli* genomes when compared to the reference genome.

Core vs pan genome

Comparison between the core and pan genomes of 60 MDR *E. coli* isolates revealed 2258 core genes across all 60 isolates among the 17944 total gene clusters. This includes 600 soft core genes in 57 to 59 isolates, 3984 shell genes in 9 to 57 isolates and 11102 genes in less than 9 isolates (Fig 1).

Serotype prediction. Serotypes were established from the whole genome data and O102:H6 was the most common serotype (18.75%), followed by O89:H9 (15.6%), O8:H9 (12.5%), O89:H5 (9.4%) and other serotypes (S1 Table).

Genetic virulence factors of MDR *E. coli*. Three common virulence gene profiles were observed among the isolates as follows, i) *iss*, *capU*, *gad*, ii) *ipfA*, and iii) *eilA*, *gad*, *air*. The FimH virulence typing revealed the types 5, 24, 27, 28, 30, 35, 54, 191 and 54-like in comparison to the fimH database.

Comparison of virulence and clonal traits. The virulence gene profiles of the 60 isolates were compared to the FimH virulence types, MLST sequence type and SNP phylogeny. The isolates clustered in two distinct groups including ST-131(H-30 clade), based on the virulence genes identified (Fig 2). The sequence types were found to be tightly linked to the groups of virulence gene profile and FimH types.

Antimicrobial resistance genetic determinants. ResFinder revealed the presence of multiple AMR genes in each of the MDR *E. coli* (Fig 3). Aminoglycoside and beta lactam resistance genes were the most dominant. The most common aminoglycoside resistance genes were *aadA5* and *aac(6')lb-cr*, followed by *aadA2* and *rmtB*, while *bla_{CTX-M-15}* followed by *bla_{NDM-5}*, *bla_{OXA-1}* and *bla_{TEM-1B}* were most prevalent among beta lactamases. Most of the isolates also




Fig 1. Pan genome vs core genome comparison depicting number of pan genes and conserved genes (A), Distribution of core genes, soft core genes and pan genes among the 60 MDR *E. coli* isolates from BSI (B).

<https://doi.org/10.1371/journal.pone.0220428.g001>

harboured *mphA*, *catB4*, *sul1*, *tetB*, *dfrA17* and *dfrA12*. Interestingly, two isolates, B7532 and B9021 carried *mcr-1.1*, which is responsible for plasmid-mediated colistin resistance. The two isolates also showed phenotypic resistance to colistin with high MIC (>32 µg/ml). In addition, the phenotypic resistance for other antimicrobials exhibited significant correlation (>80%) with the presence of respective AMR genes.

Discussion

The increasing use of third-generation β-lactams and β-lactam inhibitors was accompanied with increases in prevalence of the MDR phenotype among *E. coli*. The susceptibility profiles noted in invasive *E. coli* isolates of our study were similar to the previously (2014–2016) reported susceptibility to cefoxitin 53%, ceftazidime 33%, cefotaxime 26%, ceftriaxone 25%, cefepime 29%, piperacillin tazobactam 66%, imipenem and meropenem 89%, aztreonam 36%, ciprofloxacin 19%, levofloxacin 23%, and amikacin 91% [16]. Among these, about 64% of *E. coli* were found to be ESBL producers.

On genotypic characterization of MDR *E. coli* isolates, the increasing frequency of antimicrobial resistance in clinical *E. coli* isolates was found to be associated with *bla*_{CTX-M}, *bla*_{NDM}, and *mcr* genes. In our study, multiple AMR genes for beta lactams, carbapenems, fluoroquinolones, tetracycline, aminoglycosides and colistin were identified. The presence of genotypic AMR genes correlated well with phenotypic expression for beta lactams, carbapenems, fluoroquinolones and tetracycline. Plasmids IncFII majorly carried AMR genes *bla*_{CTX-M-15}, *bla*_{NDM-5}, *aadA2*, *rmtB*, *sul1*, *drfA12*, *erm(B)* and *tetA*, while IncFI plasmids carried mostly *aadA5*, *sul2*, *dfrA17*, *mph(A)* and *tetB* genes. Results from plasmid analysis of the study isolates were previously published elsewhere [17].

The MDR *E. coli* isolates phylogenetically grouped into four major clades: ST167, ST410, ST405 and ST131. Variant *bla*_{NDM-5}, responsible for carbapenem resistance was common in




Fig 2. SNP phylogeny based comparison of genetic virulence traits observed in MDR *E. coli* strains. Sequence types, virulence gene profile, O and H antigens and Fim-H types are shown next to the tree.

<https://doi.org/10.1371/journal.pone.0220428.g002>

comparison to other *bla*_{NDM} variants. The *bla*_{NDM} positive isolates belonging to ST410 and ST405 harboured only the *bla*_{NDM-5} variant, whereas ST167 and ST131 isolates had *bla*_{NDM-4} and *bla*_{NDM-1} respectively, in addition to *bla*_{NDM-5}. Interestingly only two isolates out of 60 MDR *E. coli* had *bla*_{NDM-1}, while it is still common among other species of MDR clinical pathogens in India [18]. From Hong Kong, a previous report identified *bla*_{NDM-1} as common among *E. coli* though the sample size was lesser [19], whereas in central China, *bla*_{NDM-1} and *bla*_{NDM-5} occurrence in *E. coli* has been reported in equal numbers [20].

Globally, *bla*_{OXA-48} type were the most commonly reported carbapenemases among *E. coli* [21], followed by *bla*_{NDM} [22], *bla*_{IMP} [23] and *bla*_{KPC} [24]. Studies have reported occurrence of *bla*_{OXA-48} from as low as 3% to 22% [25, 9]. In contrast, a previous report from India on carbapenem-resistant clinical *E. coli* isolates from 2013 and 2015 has shown that *bla*_{NDM} was common among carbapenemases in *E. coli* (70%), followed by *bla*_{OXA-48} (24%) and *bla*_{VIM} (17%). Co-occurrences of *bla*_{NDM} along with *bla*_{OXA} (5%) and *bla*_{VIM} (17%) have also been reported [26]. Similar results were seen in our study and the combinations observed were only *bla*_{NDM}+*bla*_{OXA-1}. Though, *bla*_{OXA-181} was rare in combination with *bla*_{NDM} (*n* = 1). These




Fig 3. Antimicrobial resistance genes observed in MDR *E. coli* compared to the SNP based phylogeny. Depicting prevalence of *bla*_{NDM-5} among carbenemases and *bla*_{CTX-M-15} among cephalosporinases.

<https://doi.org/10.1371/journal.pone.0220428.g003>

observations confirm that *bla*_{NDM} is prevalent among *E. coli* followed by *bla*_{OXA} in India, which is otherwise the most prevalent elsewhere.

There has been a global concern on aminoglycoside resistance in Gram-negatives. Acquired 16S-RMTases are known to confer extremely high level of aminoglycoside resistance, due to which key aminoglycosides including gentamicin, tobramycin, and amikacin are ineffective against carbenem resistant strains [27]. Accordingly, plazomicin, a new aminoglycoside agent identified to combat against carbenem-resistant Enterobacteriaceae, was found inactive if the isolates co-produced 16S-RMTases [28]. In this study, ~ 95% of the RMTase positive *E. coli* co-harboured carbenemases, which worryingly contributes to the already high burden of carbenem resistance. Similar to our study, Taylor et al. [29] and Poirel et al. [30] have reported 83.1% and 45.4% co-occurrence of carbenemases in 16S RMTase producing Enterobacteriaceae, respectively.

Our study shows that, for cephalosporin resistance, the isolates from ST131 and ST405 clades carried *bla*_{CTX-M-15} in 100% and 92% of their respective clades, whereas ST167 and ST410 isolates carried 18% and 43% *bla*_{CMY} genes in addition to 63% and 100% *bla*_{CTX-M-15}. However, 54.34% *bla*_{CTX-M} was reported previously in ESBL positive isolates from India [31]. Among the study isolates, ST167 carried significantly ($P < 0.05$) lesser *bla*_{CTX-M-15} in comparison to other clades. Similarly, ST167 and ST410 carried *bla*_{CMY} in addition for cephalosporin resistance which was not seen in ST131 and ST405. Recently, plasmid-mediated colistin resistance is being increasingly reported in *E. coli* [32–34]. This study also observed two isolates (B7532, B9021) with *mcr-1.1* expressing high MIC of >32 µg/ml to colistin and both the isolates, from the same time period and ward, were closely related with same sequence type (ST624). After this observation made in 2007 strains, there have been no reports of *mcr*.

The antimicrobial susceptibility of *E. coli* has been shown to vary geographically [35]. Among the different clonal groups observed elsewhere, *E. coli* ST131 was previously reported to be most commonly associated with community acquired infection [36–37], which recently were highly associated with healthcare settings. Also, ST131 was reported earlier as the predominant lineage carrying *bla*_{CTX-M-15} and other ESBLs. Most of the MDR *E. coli* carrying *bla*_{CTX-M-15} from different countries in Europe and North America were homogeneously grouped into the *E. coli* O25:H4-ST131 [6,36–37]. In our study, 87% of the isolates carried *bla*_{CTX-M-15}, among various STs, with only nine isolates of ST131. Among the observed STs in this study, *bla*_{CTX-M-15} was previously reported for its association with ST617, ST405 and ST131 [37].

Though ST131 clones were predominantly reported worldwide, the STs observed in our study were striking for clustering in distinct phylogenetic lineages. ST167 was previously reported for its ability to carry *bla*_{NDM} genes in China [38–40]. ST405 has been known as another global clonal group similar to ST131 [41] and has been reported to carry *bla*_{NDM} genes in hospital settings [42], in addition to *bla*KPC-2 [43]. ST405 was reported as a lineage, carrying fluoroquinolone resistance in Japan [41]. Recently, ST410 was reported as a possible international high risk clone with B2/H24R, B3/H24Rx, and B4/H24RxC AMR clades. B3/H24Rx was reported to be evolved by acquisition of the *bla*_{CTX-M-15} and an IncFII plasmid. B4/H24RxC emerged by acquiring IncX3 plasmid with *bla*_{OXA-181} known for carbapenem resistance, which further acquired *bla*_{NDM-5}, on a conserved IncFII plasmid [44]. In this study, all ST410 isolates ($n = 7$) harboured *bla*_{CTX-M-15} gene, while only B25762, BV643, B12243 and B32605 had IncFII plasmids and *bla*_{NDM-5} (B3/H24RxC). B12243, in addition harboured IncX3 with *bla*_{OXA-181} (B4/H24RxC), while BA22372 and BA9615 had only *bla*_{OXA-181} in IncX3 plasmid (B4/H24RxC).

Virulence genes observed among the *E. coli* isolates varied according to the different clades observed. The comparison of the virulence gene type with SNP based phylogeny revealed the acquisition and deletion of virulence genes. Genes *iss*, *capU* and *gad* were observed in ST167 clade. ST131 possessed *iha*, *sat*, *cnfl* and *senB*, in addition to *iss* and *gad*. ST131 strains in our study have lost the *capU* genes. Further, ST405 clade also lost *iss* and gained *eilA* and *air* genes with FimH type 29. Few isolates of ST405 retained *iha* and *sat* genes belonging to FimH 27 type within ST405. ST410 (FimH 24) that predominantly had *ipfA* gene, on the contrary, lost all other genes, except *gad* gene in two isolates. Overall, *gad* gene served as backbone for ST167, ST131 and ST405 clades, while *ipfA* was consistent in ST410. Ours is the first study that compares the evolution of virulence pattern with phylogeny, which explains the emergence of a stable clinical virulent phenotype.

FimH, that had been reported as a major candidate for the development of a vaccine against pathogenic *E. coli* [45] is responsible for producing mannose-sensitive bacterial adhesion [45]. Though high nucleotide conservation of >98% was observed in *fimH* alleles, minor sequence differences have been reported to correlate with differential binding and adhesion phenotypes [46]. Fim-H types in our study correlated well with the STs.

Our study shows that with a SNPs based phylogeny, higher discrimination between the clinical MDR *E. coli* isolates is apparent. Therefore, more such studies with integrated approach to analysing pathogenic *E. coli* in India are required to fully understand and follow the dynamic virulence and AMR landscape of this rapidly evolving group of pathogens.

Conclusions

To the best of our knowledge, this is the first report on SNP phylogeny in comparison with AMR and virulence traits in *E. coli* in India. The study revealed the prevalence of *bla*_{NDM-5} among the clades ST131, ST405 and ST410 clades. *bla*_{CTX-M-15} was responsible for

cephalosporin resistance in ST131 and ST405 clades whereas, ST167 and ST410 carried both *bla*_{CTX-M-15} and *bla*_{CMY} genes. For aminoglycoside resistance, *rmtB* was positive for 31.7% of the isolates, of which 30% were co-harboring carbapenemases. The FimH types and virulence gene profile positively correlated with the SNP based phylogeny. However the predominant ST131 epidemic clone was smaller in our study population while ST167 and ST405 clones with multiple AMR genes were predominant. Further larger studies are needed to rule out any possible bias. Isolates with *iss*, *capU* and *gad* virulence genes were the major type. Moreover, SNP based phylogeny revealed evolution of the MDR clones among the study population, which suggests that continuous WGS level molecular surveillance would be necessary to keep track of the spread of MDR clones in India.

Supporting information

S1 Table. Serotype and antimicrobial resistance profiles of MDR *E. coli* from blood stream infections (*n* = 60).

(DOCX)

S1 Fig. Circular genome plot comparing 60 MDR *E. coli* thereby showing differences in genome composition in comparison to the reference genome NC000913 *E. coli*.

(TIF)

Acknowledgments

The authors thank the Christian Medical College, Vellore, India for providing basic infrastructure required for this study.

Author Contributions

Conceptualization: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan, Shalini Anandan, Ramya Iyadurai.

Data curation: Naveen Kumar Devanga Ragupathi, Dhiviya Prabaa Muthuirulandi Sethuvel, Karthick Vasudevan, Ayyan Raj Neeravi, Jones Lionel Kumar Daniel, Ankur Mutreja.

Formal analysis: Dhiviya Prabaa Muthuirulandi Sethuvel, Ayyan Raj Neeravi, Sowmya Sathyendra, Ankur Mutreja.

Investigation: Naveen Kumar Devanga Ragupathi, Shalini Anandan, Karthick Vasudevan, Jones Lionel Kumar Daniel, Ramya Iyadurai.

Methodology: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan, Dhiviya Prabaa Muthuirulandi Sethuvel, Ayyan Raj Neeravi, Jones Lionel Kumar Daniel.

Project administration: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan.

Resources: Ayyan Raj Neeravi, Jones Lionel Kumar Daniel, Sowmya Sathyendra, Ramya Iyadurai.

Software: Naveen Kumar Devanga Ragupathi.

Supervision: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan, Shalini Anandan.

Validation: Naveen Kumar Devanga Ragupathi, Sowmya Sathyendra.

Visualization: Karthick Vasudevan, Ramya Iyadurai, Ankur Mutreja.

Writing – original draft: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan, Dhiviya Prabaa Muthuirulandi Sethuvel, Karthick Vasudevan.

Writing – review & editing: Naveen Kumar Devanga Ragupathi, Balaji Veeraraghavan, Shalini Anandan, Sowmya Sathyendra, Ramya Iyadurai, Ankur Mutreja.

References

1. Kennedy KJ, Roberts JL, Collignon PJ. *Escherichia coli* bacteraemia in Canberra: incidence and clinical features. *Med J Aust.* 2008; 188:209–13. PMID: [18279126](https://pubmed.ncbi.nlm.nih.gov/18279126/)
2. López-Banda DA, Carrillo-Casas EM, Leyva-Leyva M, Orozco-Hoyuela G, Manjarrez-Hernández AH, Arroyo-Escalante S, et al. Identification of Virulence Factors Genes in *Escherichia coli* Isolates from Women with Urinary Tract Infection in Mexico. *BioMed Research International*, Volume 2014, Article ID 959206, 10 pages. <http://dx.doi.org/10.1155/2014/959206>
3. Johnson JR, Sannes MR, Croy C, Johnston B, Clabots C, Kuskowski MA, et al. Antimicrobial drug-resistant *Escherichia coli* from humans and poultry products, Minnesota and Wisconsin, 2002–2004. *Emerg Infect Dis.* 2007; 13:838–46. <https://doi.org/10.3201/eid1306.061576> PMID: [17553221](https://pubmed.ncbi.nlm.nih.gov/17553221/)
4. Mesa RJ, Blanc V, Blanch AR, Cortés P, González JJ, Lavilla S et al. Extended-spectrum β -lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms, and sewage). *J Antimicrob Chemother.* 2006; 58:211–5. <https://doi.org/10.1093/jac/dk211> PMID: [16720567](https://pubmed.ncbi.nlm.nih.gov/16720567/)
5. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli*: importance of international travel. *J Infect.* 2008; 57:441–448. <https://doi.org/10.1016/j.jinf.2008.09.034> PMID: [18990451](https://pubmed.ncbi.nlm.nih.gov/18990451/)
6. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM. Intercontinental emergence of *Escherichia coli* clone O25:H4–ST131 producing CTX-M-15. *J Antimicrob Chemother.* 2008; 61:273–81. <https://doi.org/10.1093/jac/dkm464> PMID: [18077311](https://pubmed.ncbi.nlm.nih.gov/18077311/)
7. Lau SH, Kaufmann ME, Livermore DM, Woodford N, Willshaw GA, Cheasty T. UK epidemic *Escherichia coli* strains A–E, with CTX-M-15 β -lactamase, all belong to the international O25:H4–ST131 clone. *J Antimicrob Chemother.* 2008; 62:1241–4. <https://doi.org/10.1093/jac/dkn380> PMID: [18779256](https://pubmed.ncbi.nlm.nih.gov/18779256/)
8. Alhashash F, Weston V, Diggle M, McNally A. Multidrug-Resistant *Escherichia coli* Bacteremia. *Emerg Infect Dis.* 2013; 19(10):1699–701. <https://doi.org/10.3201/eid1910.130309> PMID: [24050656](https://pubmed.ncbi.nlm.nih.gov/24050656/)
9. Candan ED, Aksöz N. *Escherichia Coli*: Characteristics of Carbapenem Resistance and Virulence Factors. *Braz arch biol technol.* 2017;60.
10. Nagaraj S, Chandran SP, Shamanna P, Macaden R. Carbapenem resistance among *Escherichia coli* and *Klebsiella pneumoniae* in a tertiary care hospital in south India. *Indian J Med Microbiol.* 2012; 30(1):93–5. <https://doi.org/10.4103/0255-0857.93054> PMID: [22361769](https://pubmed.ncbi.nlm.nih.gov/22361769/)
11. Kanamori H, Parobek CM, Juliano JJ, Johnson JR, Johnston BD, Johnson TJ, Weber DJ, et al. Genomic Analysis of Multidrug-Resistant *Escherichia coli* from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-H30Rx and ST131-H30R1 Strains. *Antimicrob Agents Chemother.* 2017; 61(8):pii: e00912–17. <https://doi.org/10.1128/AAC.00912-17> PMID: [28584139](https://pubmed.ncbi.nlm.nih.gov/28584139/)
12. Abbott SL, Cheung WKW, Janda JM. The genus *Aeromonas*: biochemical characteristics, atypical reactions, and phenotypic identification schemes. *J Clin Microbiol.* 2003; 41:2348–57. <https://doi.org/10.1128/JCM.41.6.2348-2357.2003> PMID: [12791848](https://pubmed.ncbi.nlm.nih.gov/12791848/)
13. Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O. Solving the Problem of Comparing Whole Bacterial Genomes across Different Sequencing Platforms. *PLoS ONE* 2014; 9(8):e104984. <https://doi.org/10.1371/journal.pone.0104984> PMID: [25110940](https://pubmed.ncbi.nlm.nih.gov/25110940/)
14. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: Rapid large-scale prokaryote pan genome analysis. *Bioinformatics.* 2015; 31(22):3691–3. <https://doi.org/10.1093/bioinformatics/btv421> PMID: [26198102](https://pubmed.ncbi.nlm.nih.gov/26198102/)
15. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res.* 2014; <https://doi.org/10.1093/nar/gku1196> PMID: [25414349](https://pubmed.ncbi.nlm.nih.gov/25414349/)
16. Veeraraghavan B, Jesudason MR, Prakasah JAJ, Anandan S, Sahni RD, Pragasam AK, et al. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014–2016: Study for monitoring antimicrobial resistance trend report. *Indian J Med Microbiol.* 2018; 36:32–6. https://doi.org/10.4103/ijmm.IJMM_17_415 PMID: [29735823](https://pubmed.ncbi.nlm.nih.gov/29735823/)
17. Ragupathi NKD, Bakthavatchalam YD, Mathur P, Pragasam AK, Walia K, Ohri VC, et al. Plasmid profiles among some ESKAPE pathogens in a tertiary care centre in south India. *Indian J Med Res.* 2019; 149(2):222–31. https://doi.org/10.4103/ijmr.IJMR_2098_17 PMID: [31219087](https://pubmed.ncbi.nlm.nih.gov/31219087/)

18. Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, Ralph R. Carbapenem resistant *Klebsiella pneumoniae* isolated from bloodstream infection: Indian experience. *Pathog glob health*. 2017; 111(5):240–6. <https://doi.org/10.1080/20477724.2017.1340128> PMID: 28670975
19. Ho PL, Cheung YY, Wang Y, Lo WU, Lai EL, Chow KH, et al. Characterization of carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* from a healthcare region in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2016; 35(3):379–85. <https://doi.org/10.1007/s10096-015-2550-3> PMID: 26740321
20. Liang WJ, Liu HY, Duan GC, Zhao YX, Chen SY, Yang HY, et al. Emergence and mechanism of carbapenem-resistant *Escherichia coli* in Henan, China, 2014. *J Infect Public Health*. 2018; 11(3):347–51. <https://doi.org/10.1016/j.jiph.2017.09.020> PMID: 29107607
21. Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. *Semin Respir Crit Care Med*. 2015; 36(1):74–84. <https://doi.org/10.1055/s-0035-1544208> PMID: 25643272
22. Mushtaq S, Irfan S, Sarma JB, Doumith M, Pike R, Pitout J et al. Phylogenetic diversity of *Escherichia coli* strains producing NDM-type carbapenemases. *J Antimicrob Chemother*. 2011; 66:2002–5. <https://doi.org/10.1093/jac/dkr226> PMID: 21669947
23. Aktas Z, Satana D, Kayacan C, Ozbek B, Gurler N, Somer A et al. Carbapenem resistance in Turkey: Repeat report on OXA-48 in *Klebsiella pneumoniae* and first report on IMP-1 beta-lactamase in *Escherichia coli*. *Afr J Microbiol Res*. 2012; 6:3874–8.
24. Morris D, Boyle F, Ludden C, Condon I, Hale J, O'Connell N et al. Production of KPC-2 Carbapenemase by an *Escherichia coli* Clinical Isolate Belonging to the International ST131 Clone. *Antimicrob Agents Chemother*. 2011; 55:4935–6. <https://doi.org/10.1128/AAC.05127-11> PMID: 21768521
25. Budak S, Oncul O, Aktas Z, Acar A, Ozyurt M, Turhan V, et al. The determination of carbapenem resistance in *Escherichia coli* and *Pneumoniae* isolates related to nosocomial infections and the evaluation of risk factors. *Southeast Asian J Trop Med Public Health*. 2014; 45(1):113–22. PMID: 24964660
26. Sharma A, Bakthavatchalam YD, Gopi R, Anandan S, Verghese VP, Veeraraghavan B. Mechanisms of Carbapenem Resistance in *K. pneumoniae* and *E. coli* from Bloodstream Infections in India. *J Infect Dis Ther*. 2016; 4:293.
27. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases. *Infect Dis Clin North Am*. 2016; 30(2): 523–37. <https://doi.org/10.1016/j.idc.2016.02.011> PMID: 27208771
28. Yu F, Wang L, Pan J, Yao D, Chen C, Zhu T, et al. Prevalence of 16S rRNA methylase genes in *Klebsiella pneumoniae* isolates from a Chinese teaching hospital: coexistence of *rmtB* and *armA* genes in the same isolate. *Diagn Microbiol Infect Dis*. 2009; 64:57–63. <https://doi.org/10.1016/j.diagmicrobio.2009.01.020> PMID: 19232867
29. Taylor E, Sriskandan S, Woodford N, Hopkins KL. High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland. *Int J Antimicrob Agents*. 2018; 52(2):278–82. <https://doi.org/10.1016/j.ijantimicag.2018.03.016> PMID: 29596903
30. Poirel L, Goutines J, Aires-de-Sousa M, Nordmann P. High Rate of Association of 16S rRNA Methylases and Carbapenemases in Enterobacteriaceae Recovered from Hospitalized Children in Angola. *Antimicrob Agents Chemother*. 2018; 62:e00021–18. <https://doi.org/10.1128/AAC.00021-18> PMID: 29439957
31. Ravikant, Kumar P, Ranotkar S, Zutshi S, Lahkar M, Phukan C, et al. Prevalence and identification of extended spectrum β -lactamases (ESBL) in *Escherichia coli* isolated from a tertiary care hospital in North-East India. *Ind J Exp Biol*. 2016; 54:108–114.
32. Elnahiry SS, Khalifa HO, Soliman AM, Ahmed AM, Hussein AM, Shimamoto T, et al. Emergence of Plasmid-Mediated Colistin Resistance Gene *mcr-1* in a Clinical *Escherichia coli* Isolate from Egypt. *Antimicrob Agents Chemother*. 2016; 60(5):3249–50. <https://doi.org/10.1128/AAC.00269-16> PMID: 26953204
33. Ghafur A, Shankar C, GnanaSoundari P, Venkatesan M, Mani D, Thirunaryanan MA, et al. Detection of chromosomal and plasmid-mediated mechanisms of colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae* from Indian food samples. *J Glob Antimicrob Resist*. 2019; 16:48–52. <https://doi.org/10.1016/j.jgar.2018.09.005> PMID: 30244040
34. Yang F, Shen C, Zheng X, Liu Y, El-Sayed Ahmed MAE, Zhao Z, et al. Plasmid-mediated colistin resistance gene *mcr-1* in *Escherichia coli* and *Klebsiella pneumoniae* isolated from market retail fruits in Guangzhou, China. *Infect Drug Resist*. 2019; 12:385–9. <https://doi.org/10.2147/IDR.S194635> PMID: 30809099
35. Ikram R, Psutka R, Carter A, Priest P. An outbreak of multi-drug resistant *Escherichia coli* urinary tract infection in an elderly population: a case-control study of risk factors. *BMC Infect Dis*. 2015; 15:224. <https://doi.org/10.1186/s12879-015-0974-0> PMID: 26054866
36. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, et al. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum- β -lactamase-producing *Escherichia coli* among

- companion animals. *J Antimicrob Chemother.* 2010; 65:651–60. <https://doi.org/10.1093/jac/dkq004> PMID: [20118165](https://pubmed.ncbi.nlm.nih.gov/20118165/)
37. Brolund A, Edquist PJ, Makitalo B, Olsson-Liljequist B, Soderblom T, Wisell KT, et al. Epidemiology of extended-spectrum b-lactamase-producing *Escherichia coli* in Sweden 2007–2011. *Clin Microbiol Infect.* 2014; 20:O344–O352. <https://doi.org/10.1111/1469-0691.12413> PMID: [24118431](https://pubmed.ncbi.nlm.nih.gov/24118431/)
 38. Yang P, Xie Y, Feng P, Zong Z. *bla*NDM-5 Carried by an IncX3 Plasmid in *Escherichia coli* Sequence Type 167. *Antimicrob Agents Chemother.* 2014; 58(12):7548–52. <https://doi.org/10.1128/AAC.03911-14> PMID: [25246393](https://pubmed.ncbi.nlm.nih.gov/25246393/)
 39. Feng Y, Yang P, Xie Y, Wang X, McNally A, Zong Z. *Escherichia coli* of sequence type 3835 carrying *bla*NDM-1, *bla*CTX-M-15, *bla*CMY-42 and *bla*SHV-12. *Sci Rep.* 2015; 5:12275. <https://doi.org/10.1038/srep12275> PMID: [26194736](https://pubmed.ncbi.nlm.nih.gov/26194736/)
 40. Shen P, Yi M, Fu Y, Ruan Z, Du X, Yu Y, et al. Detection of an *Escherichia coli* Sequence Type 167 Strain with Two Tandem Copies of *bla*NDM-1 in the Chromosome. *J Clin Microbiol.* 2017; 55:199–205. <https://doi.org/10.1128/JCM.01581-16> PMID: [27807154](https://pubmed.ncbi.nlm.nih.gov/27807154/)
 41. Matsumura Y, Yamamoto M, Nagao M, Ito Y, Takakura S, Ichiyama S, et al. Association of Fluoroquinolone Resistance, Virulence Genes, and IncF Plasmids with Extended-Spectrum-β-Lactamase-Producing *Escherichia coli* Sequence Type 131 (ST131) and ST405 Clonal Groups. *Antimicrob Agents Chemother.* 2013; 57(10):4736–42. <https://doi.org/10.1128/AAC.00641-13> PMID: [23856781](https://pubmed.ncbi.nlm.nih.gov/23856781/)
 42. Zhang X, Feng Y, Zhou W, McNally A, Zong Z. Cryptic transmission of ST405 *Escherichia coli* carrying *bla*NDM-4 in hospital. *Sci Rep.* 2018; 8:390. <https://doi.org/10.1038/s41598-017-18910-w> PMID: [29321680](https://pubmed.ncbi.nlm.nih.gov/29321680/)
 43. Cai JC, Zhang R, Hu YY, Zhou HW, Chen GX. Emergence of *Escherichia coli* Sequence Type 131 Isolates Producing KPC-2 Carbapenemase in China. *Antimicrob Agents Chemother.* 2014; 58(2):1146–52. <https://doi.org/10.1128/AAC.00912-13> PMID: [24323475](https://pubmed.ncbi.nlm.nih.gov/24323475/)
 44. Roer L, Overballe-Petersen S, Hansen F, Schønning K, Wang M, Røder BL, et al. *Escherichia coli* Sequence Type 410 Is Causing New International High-Risk Clones. *mSphere.* 2018; 3(4):pii: e00337–18. <https://doi.org/10.1128/mSphere.00337-18> PMID: [30021879](https://pubmed.ncbi.nlm.nih.gov/30021879/)
 45. Tchesnokova V, Aprikian P, Kisiela D, Gowey S, Korotkova N, Thomas W et al. Type 1 Fimbrial Adhesin FimH Elicits an Immune Response That Enhances Cell Adhesion of *Escherichia coli*. *Infect. Immun.* 2011; 79(10):3895–3904. <https://doi.org/10.1128/IAI.05169-11> PMID: [21768279](https://pubmed.ncbi.nlm.nih.gov/21768279/)
 46. Bouckaert J, Mackenzie J, de Paz JL, Chipwaza B, Choudhury D, Zavialov A et al. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of *Escherichia coli* pathotypes. *Mol Microbiol.* 2006; 61(6):1556–1568. <https://doi.org/10.1111/j.1365-2958.2006.05352.x> PMID: [16930149](https://pubmed.ncbi.nlm.nih.gov/16930149/)